A. Scarfe

发表

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

John R. Mackey, Fiona Campbell, David Goldstein, 2014, Journal of the National Cancer Institute.

A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.

J. Mackey, C. Cass, M. Sawyer, 2016, Clinical breast cancer.

The role of bevacizumab in colorectal cancer: understanding its benefits and limitations

J. Spratlin, A. Scarfe, K. Mulder, 2011, Expert opinion on biological therapy.

Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma

K. King, A. Scarfe, O. Abdel-Rahman, 2021, American journal of clinical oncology.

Integration of Palliative Care with Alternative Medicine in Patients who have Refused Curative Cancer Therapy: A Report of Two Cases

E. Bruera, A. Scarfe, C. Jenkins, 1998, Journal of palliative care.

Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.

J. Mackey, M. Smylie, H. Au, 2004, Clinical breast cancer.

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial

J. Hecht, Y. Bang, M. Sawyer, 2017, JAMA oncology.

Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients?

A. Abraham, J. Easaw, M. Iafolla, 2022, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adherence to treatment guidelines in stage II/III rectal cancer in Alberta, Canada.

M. Winget, Y. Yasui, A. Scarfe, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

M. Büchler, J. Neoptolemos, M. Lerch, 2012, JAMA.

Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future

Q. Chu, K. King, J. Spratlin, 2010, Oncotarget.

Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer.

M. Winget, C. Butts, K. King, 2013, International journal for quality in health care : journal of the International Society for Quality in Health Care.

Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.

M. Büchler, J. Neoptolemos, J. Izbicki, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity

Tony Reiman, Vickie E Baracos, L. Mccargar, 2007, Clinical Cancer Research.

The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma

J. Kleeff, M. Büchler, J. Neoptolemos, 2017, Annals of surgery.

Survival of metastatic colorectal cancer patients treated with chemotherapy in Alberta (1995–2004)

Z. Qiu, H. Bryant, A. Scarfe, 2009, Supportive Care in Cancer.

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer

J. Mackey, W. Greenhalf, J. Neoptolemos, 2018, British Journal of Cancer.

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada

M. Winget, Y. Yasui, A. Scarfe, 2011, Cancer.

Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline‐recommended treatment

M. Winget, S. Hossain, Y. Yasui, 2010, Cancer.

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

J. Mackey, M. Büchler, W. Greenhalf, 2021, Cancers.

Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review

M. Winget, Y. Yasui, A. Scarfe, 2012, BMC Research Notes.

Uridine glucuronosyltransferase 2B7 pharmacogenetics predicts epirubicin clearance and myelosuppression.

J. Mackey, M. Sawyer, E. Pituskin, 2009, Journal of Clinical Oncology.

Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer.

M. Winget, C. Butts, K. King, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Timing of Adjuvant Chemotherapy and Survival in Patients with Stage II/III Rectal Cancer

M. Winget, Y. Yasui, A. Scarfe, 2012 .

M. Büchler, J. Mackey, W. Greenhalf, 2018, British Journal of Cancer.

Script-theory virtual case: A novel tool for education and research

A. Scarfe, Andrew Scarfe, Melanie Lewis, 2016, Medical teacher.

Timeliness of cancer care from diagnosis to treatment: a comparison between patients with breast, colon, rectal or lung cancer.

M. Winget, C. Butts, K. King, 2013, International journal for quality in health care : journal of the International Society for Quality in Health Care.